Can AMPLIFY data be extrapolated to use of other BTKi's in combination with venetoclax or would you only ever use acalabrutinib/venetoclax in first line?  

I think the main question here is whether AV can be extrapolated to ZV, since there is already phase 3 data with IV, and I do not think it would be appropriate to extrapolate to a non-covalent BTKi. I think it is very likely that ZV is as effective as AV, but there are not many clinical scenarios wh...

Indirect comparisons, including network meta-analyses and matching-adjusted indirect comparisons, suggest that zanubrutinib monotherapy may offer superior progression-free survival compared to fixed-duration acalabrutinib–venetoclax in low-risk, treatment-naïve CLL. However, these analyse...

I prefer NOT to extrapolate results, given that BTKis have unique spectra of kinase activities ("kinomes"), different PK/PD properties (such as half life), different adherence rates and dosing schedules, and have different synergistic (especially in a complex immune context that we are committing to...

I think zan is better than acal and less toxic, i.e., fewer headaches. Await phase III data, but I won't wait. I have an alternative regimen that I am confident can cure CLL as well as MCL FL and MZL; published, phase II completed. The regimen requires close attention to monitoring CBC and dose ad...

There are data for each BTKi with ven in first line, but the datasets are all unique. Personally, I would not use ibrutinib for safety reasons, although there is a lot of data. Zanubrutinib venetoclax has data from SEQUOIA as an MRD-driven regimen, but most patients stay on the zanu. I have started ...